NCT00234819

Study Evaluating Bazedoxifene/Conjugated Estrogen Combinations in Symptoms Associated With Menopause

A Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Bazedoxifene/Conjugated Estrogen Combinations for Treatment of Vasomotor Symptoms Associated With Menopause

• Status: Completed
• Phase: Phase 3
• Study type: Interventional
• Enrollment: 325 (planned)
• Sponsor: Wyeth is now a wholly owned subsidiary of Pfizer · Industry
• Sex: Female
• Age: 40 Years – 64 Years
• Healthy volunteers: Not accepted

Summary

The purpose of this study is to determine whether bazedoxifene/conjugated estrogens combinations are effective in the treatment of moderate to severe vasomotor symptoms associated with menopause.

Conditions

• Vasomotor Symptoms Associated With Menopause

Interventions

Type	Name	Description
DRUG	Bazedoxifene/Conjugated Estrogen

Timeline

• Start date: 2005-10-01
• Completion: 2007-02-01
• First posted: 2005-10-07
• Last updated: 2007-12-28

Locations

7 sites across 1 country: United States